RSV can be deadly-especially for older adults. Why aren't more of them getting the new vaccine?RSV vaccine awareness is rising, but COVID-19 fatigue impedes uptake among older adults, with less than 25% vaccinated as of spring 2024.
NHS starts vaccinating pregnant women and older people for RSV- who is eligible?The NHS is introducing an RSV vaccine for pregnant women and older adults to reduce serious illness and hospital admissions this winter.
FDA approves first RSV vaccine for at-risk adults in their 50sFDA approved GSK's RSV vaccine for age 50+, expanding from age 60+.CDC may recommend vaccination for adults 50-59, enhancing public health benefits.
Moderna secures a second FDA vaccine approval as Spikevax sales plummetModerna's mRESVIA vaccine approved by FDA for adults 60 and older, showing high efficacy against RSV.
FDA approves first RSV vaccine for at-risk adults in their 50sFDA approved GSK's RSV vaccine for age 50+, expanding from age 60+.CDC may recommend vaccination for adults 50-59, enhancing public health benefits.
Moderna secures a second FDA vaccine approval as Spikevax sales plummetModerna's mRESVIA vaccine approved by FDA for adults 60 and older, showing high efficacy against RSV.
C.D.C. Scales Back Recommendations for R.S.V. VaccineThe CDC has updated its recommendations on RSV vaccine to include a lifetime dose for individuals aged 75 and older, while only endorsing it for specific health conditions in adults aged 60-74.
Young Adults May Soon Be Able to Get an RSV ShotPfizer's RSV shot showed strong immune reactions in young adults at higher risk, prompting plans for extended U.S. approval.The adult vaccine market for RSV is expected to be lucrative, with Pfizer aiming to increase its market share.
C.D.C. Scales Back Recommendations for R.S.V. VaccineThe CDC has updated its recommendations on RSV vaccine to include a lifetime dose for individuals aged 75 and older, while only endorsing it for specific health conditions in adults aged 60-74.
Young Adults May Soon Be Able to Get an RSV ShotPfizer's RSV shot showed strong immune reactions in young adults at higher risk, prompting plans for extended U.S. approval.The adult vaccine market for RSV is expected to be lucrative, with Pfizer aiming to increase its market share.